title: Renal cell carcinoma: new insights and challenges for a clinician scientist.
abstract: There is a growing recognition of the complex interplay between renal cell cancer (RCC), kidney function, mechanical reduction of nephron mass, and systemic agents targeting the cancer. Earlier detection of RCC and rising life expectancy of cancer survivors places a greater emphasis on preservation of renal function after cancer resection and during systemic therapy. Unique adverse effects associated with RCC drugs not only help reveal cancer pathophysiology but also expand our knowledge of normal cell signaling and metabolism. In this review, we outline our current understanding of RCC biology and treatment, their bidirectional relationship with kidney function, and unmet research needs in this field.
authors.affiliation: Renal Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Roman
authors.initials: R
authors.lastname: Shingarev
authors.affiliation: Renal Service, Memorial Sloan-Kettering Cancer Center, New York, New York jaimese@mskcc.org.
authors.forename: Edgar A
authors.initials: EA
authors.lastname: Jaimes
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D035843:Biomedical Research / Q000379:methods*; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy; D020022:Genetic Predisposition to Disease; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy; D058990:Molecular Targeted Therapy; D009392:Nephrectomy; D010641:Phenotype; D010820:Physicians; D012108:Research Personnel
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: molecularly targeted therapy and immune checkpoint inhibition; radical and partial nephrectomy; renal cell carcinoma genotyping